CG
ZYNE

Cutler Group’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Cutler Group’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-13,100
Closed -$2K – 5391
2020
Q2 		$2K Buy
+13,100
New +$61.9K ﹤0.01% 3886
2019
Q3 		– Sell
-1,800
Closed -$2K – 4870
2019
Q2 		$2K Buy
+1,800
New +$20.8K ﹤0.01% 3703
2018
Q4 		– Sell
-11,700
Closed -$5K – 4781
2018
Q3 		$5K Buy
11,700
+5,900
+102% +$45.3K ﹤0.01% 3100
2018
Q2 		$2K Sell
5,800
-4,000
-41% -$41K ﹤0.01% 3680
2018
Q1 		$5K Sell
9,800
-40,700
-81% -$439K ﹤0.01% 3340
2017
Q4 		$95K Sell
50,500
-16,800
-25% -$193K ﹤0.01% 1411
2017
Q3 		$67K Sell
67,300
-97,900
-59% -$1.04M ﹤0.01% 1987
2017
Q2 		$153K Sell
165,200
-90,100
-35% -$1.79M 0.01% 1496
2017
Q1 		$1.51M Buy
255,300
+42,700
+20% +$849K 0.06% 257
2016
Q4 		$1.19M Buy
212,600
+170,400
+404% +$2.29M 0.04% 351
2016
Q3 		$81K Buy
+42,200
New +$401K ﹤0.01% 1993

Other funds holding ZYNE

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
IEFM
IQ EQ Fund Management Dublin 2, Ireland $1.57B AUM 40.42% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Cutler Group's ZYNE Position: Q1 2022 in Review

Cutler Group sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q1 2022, closing a stake of 100 shares.

Cutler Group first reported a position in ZYNE in Q3 2016 and held it in 21 quarters. The position peaked at $186K in Q3 2018. 59 funds tracked by Wall St. Rank hold ZYNE as of Q1 2022.

  • Cutler Group reported no remaining Zynerba Pharmaceuticals, Inc position as of Q1 2022 after selling out during the quarter.
  • Cutler Group sold 100 Zynerba Pharmaceuticals, Inc shares in Q1 2022.
  • Cutler Group first reported a position in Zynerba Pharmaceuticals, Inc in Q3 2016 and held it in 21 quarters.
  • Cutler Group's Zynerba Pharmaceuticals, Inc position peaked at $186K in Q3 2018.
  • 59 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q1 2022.

Based on Cutler Group's 13F filing for Q1 2022, filed 14 Apr 2022.